DocGo (US:DCGO)2026-03-16 22:00Financial Data and Key Metrics Changes - The company reported $74.9 million in revenue for Q4 2025, down from $120.8 million in Q4 2024, primarily due to the wind-down of migrant-related projects [15] - For the full year 2025, total revenue was $322.2 million compared to $616.6 million in 2024 [15] - Adjusted EBITDA loss for Q4 2025 was $11.3 million, compared to a profit of $1.1 million in Q4 2024 [16] - The adjusted gross margin for Q4 2025 was 32.5%, down from 33.5% in Q4 2024 [17] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.2 million in Q4 2025 from $49.1 million in Q4 2024 [15] - Mobile Health revenue for Q4 2025 was $24.8 million, down from $71.8 million in Q4 2024, but non-migrant Mobile Health revenues increased by 47% [16] - SteadyMD generated $6.1 million in revenue for DocGo in Q4 2025, with full-year gross margins improving from approximately 30% to 37% [6][17] Market Data and Key Metrics Changes - The company saw strong growth in markets like New York, Texas, and Tennessee, contributing to revenue increases in medical transportation [16] - The number of assigned lives in the care gap closure program increased by 12% sequentially, from 1.3 million to over 1.45 million [10] Company Strategy and Development Direction - The company is focused on integrating SteadyMD into its mobile health offerings and aims to consolidate provider networks by the end of Q2 2026 [7] - The company plans to reduce cash outlay in 2026 as early markets mature and become self-sustaining, with a goal of achieving profitability in the second half of 2026 [11] - An efficiency innovation portfolio has been launched, expected to deliver $5-$6 million in savings in 2026 and $20-$24 million in 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong demand for services and top-line growth across volume metrics, despite challenges in achieving profitability [14] - The company anticipates a full-year adjusted EBITDA loss in the range of $5 million to $10 million for 2026, an improvement from previous guidance [24] - Management highlighted the importance of technology and automation in driving efficiency and reducing costs while maintaining high service levels [70] Other Important Information - The company has initiated a process to explore strategic alternatives aimed at maximizing shareholder value [13] - Cash and cash equivalents at year-end were $68.3 million, down from $95.2 million, primarily due to the acquisition of SteadyMD and delays in collecting migrant-related accounts receivable [21][22] Q&A Session Summary Question: Can you provide details on the strategic alternatives process? - The company has engaged an investment bank to run a formal process aimed at maximizing shareholder value, but cannot share further details at this time [26] Question: What are the components driving the increased 2026 guidance? - The increase in revenue guidance is primarily driven by improved volumes in the Medical Transportation segment and additional upside from SteadyMD [28] Question: Can you quantify the free cash flow pressures in 2026? - The company expects cash balance to be lower due to working capital requirements and ongoing operating losses, but anticipates collecting outstanding receivables [33][36] Question: What is the outlook for the payer business and pipeline? - The company continues to see momentum in the payer business, with an increase in covered lives and ongoing discussions with potential new payers [41][46] Question: How should we think about EBITDA cadence throughout the year? - Most of the adjusted EBITDA loss is expected in the first half of the year, with a transition to profitability in the second half as efficiency measures take effect [68]